Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2020
Date of Report: April 17, 2020
This filing serves as a notification to the U.S. Securities and Exchange Commission regarding the convening of a Shareholders' General Meeting. The document contains a rectified meeting notice as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing regarding corporate governance and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this document. The filing focuses solely on the administrative update of the Shareholders' General Meeting notice.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the signature block and exhibit list for the meeting notice.
Investor Verification Checklist
- Verify the details of the rectified Shareholders' General Meeting notice (Exhibit 99.1) referenced in this filing.
- Confirm the date and agenda of the upcoming shareholder meeting.
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance data, as this 6-K does not contain financial metrics.